We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.00
Bid: 150.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 10.00 (6.667%)
Open: 155.00
High: 155.00
Low: 155.00
Prev. Close: 155.00
ITX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Year Results

28 Oct 2020 07:00

RNS Number : 4030D
Itaconix PLC
28 October 2020
 

28 October 2020

Itaconix plc ("Itaconix" or the "Company")

Half year results for the period ended 30 June 2020

 

Sustainable Products Drive Major Revenue Growth

 

Itaconix (LSE: ITX) (OTCQB: ITXXF), a leading innovator in sustainable specialty polymers, is pleased to announce its unaudited interim results for the six months ended 30 June 2020 ("2020").

A copy of the Interim Report & Accounts is available for download on Itaconix's website at www.itaconix.com.

Financial Highlights

Financial results for the first half of 2020 show the increasing uptake by major brands of the Company's sustainable products as key ingredients in everyday consumer goods and the significant progress made towards profitability from higher volumes across both home and personal care applications.

· First half revenues of $1.1 million were 80% higher than the first half of 2019 and 59% higher than the second half of 2019. First half revenues also represent 84% of revenues for the full year of 2019.

· Gross profits were $0.4 million, representing an increase of 129% over the first half of 2019 and 47% over the second half of 2019.

· Gross profit margin was 37% compared to 35% for the full year of 2019, remaining in line with Company expectations for a specialty ingredient company.

· Adjusted EBITDA1 was a loss of $0.6 million, compared to a loss of $1.2 million for the same period in 2019 and a loss of $1.2 million for the second half of 2019, reflecting the continued trajectory towards achieving break-even profitability from increasing revenues.

· Gross operating loss of $0.8 million, representing a decrease of 43% from losses of $1.4 million in both the first and second half of 2019.

· Cash and Cash Equivalents as at 30 June 2020 was $0.5 million, compared to $0.8 million as at 31 December 2019.

· In May 2020, Itaconix Corporation received a US Government Paycheck Protection Program Loan for $0.2m to support the business through the Covid-19 pandemic.

· In July 2020, the Company completed an equity raise with gross proceeds of $2.2 million to fund operating costs and working capital needs as revenues advance toward break-even profitability.

Operational Highlights

The acceleration in revenues is the result of the continued broadening of the customer base and advancement in customer projects in the Company's major application areas:

· Revenues increased across all of the Company's home and personal care polymers.

· Although demand for household cleaning has surged during the Covid-19 pandemic, major new revenues came from new customer products entering the market with new levels of performance, cost and sustainability.

· We introduced our new Itaconix® TSI™ 322 detergent polymer with use in two North American dishwashing detergent brands.

· The Company completed a supply agreement with New Wave Global Services Inc. ("New Wave"), a leading North American detergent supplier, on the pricing and supply of up to 1,000,000 lbs. of Itaconix detergent polymers through 2021. Volumes in the first half of 2020 exceeded management expectations.

· Demand for our ZINADOR™ odour removal polymer continues to expand into leading household brands and new regions through our collaboration with Croda.

· Revenues for our hairstyling polymer advanced through our collaboration with Nouryon.

· The Company announced its new BIO*Asterix™ line of functional additives and a joint development agreement for potential use by a leading innovator in biodegradable packaging.

Outlook

Itaconix has commercial momentum as current customer products succeed in the market and new customer products continue to progress to market in the next year. The expanding foundation of recurring revenues is creating a strong base for continued revenue growth toward the Company's goal of sustainable profitability in the coming years.

John R. Shaw, CEO of Itaconix, stated: "Major advancements in our customer pipeline allowed us to enter a new phase of commercial growth in the first half of 2020. Our customers are succeeding with new products that leverage the unique value and functionality of our sustainable ingredients. When consumers purchase these new products for their performance and cost, they also benefit the environment through a reduction in the depletion of natural resources, an increase in the use of safer chemicals, and a reduction in the release of chemicals."

 

1 Adjusted EBITDA is defined and reconciled to Operating loss in Note 4 of the Interim Report.

 

 

For further information please contact:

Itaconix plc

+1 603 775-4400

John R. Shaw / Laura Denner

 

N+1 Singer

+44 (0) 207 496 3000

Peter Steel / James Moat (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

About Itaconix

Itaconix develops and produces bio-based functional ingredient that improve the safety, performance or sustainability of consumer and industrial products, with technology and market leadership positions in non-phosphate detergents, odour control, and hair styling.

www.itaconix.com

 

 

 

 

 

Chief Executive's Statement

Itaconix is building a growing, high-gross-margin, capital-efficient company around the use of our proprietary sustainable chemistries as high-value ingredients in everyday consumer products. Our near-term focus is to reach sustainable revenues and profitability through our current efforts in non-phosphate detergents, odour control, and hair styling.

Commercial Progress

We entered a new stage of revenue growth in the first half of 2020 as important customer projects began to convert into new order volumes. Our polymers are delivered based on purchase orders received from customers to blend and produce home and personal care products. While we have some agreements with larger customers on purchasing terms, order volumes are based on the underlying demand for customers' end-products. As our customers launch and succeed in the market with new consumer products based on our bio-based polymers, our monthly revenues are increasing in size and reliability from a growing base of recurring orders. We expect these dynamics to continue as additional customer projects in our pipeline convert into new order volumes.

In January, we announced the introduction of Itaconix® TSI™ 322 as our latest advance in high-performing detergent polymers. Itaconix® TSI™ 322 is the result of our ongoing engagement with current and potential customers on a new generation of non-phosphate dishwashing detergents to meet changing consumer buying behaviour. The key formulation breakthrough with Itaconix® TSI™ 322 is the ability to deliver excellent performance while replacing multiple ingredients to achieve cost savings and more sustainable and compact detergent products.

In January, we also announced that the US Patent and Trademark Office issued a new patent to the Company for the composition of detergents containing Itaconix's novel bio-based polymers. This new patent provides the Company with an additional layer of intellectual property protection for the unique value of Itaconix polymers in non-phosphate dishwasher detergents. In addition, the new patent extends the Company's proprietary position in key detergent compositions to 2037.

Also in January, we announced the delivery of the first order of ZINADOR™ 35L to Croda. The Company had previously announced an expansion of its global supply agreement in odour control products with Croda to include both ZINADOR™ 22L and 35L. The new ZINADOR™ 35L is a more concentrated version of Itaconix's proprietary polymeric complex that delivers performance and cost advantages in detergent and industrial applications.

In February, we extended our commercial relationship with New Wave Global Services Inc. ("New Wave"), a leading North American detergent supplier, with a licensing agreement for a new dishwashing detergent formulation and a supply agreement to support the growth in the Company's polymer volumes used in New Wave products. The new dishwashing formulation is based on the competitive advantages available with Itaconix® TSI™ 322. Roll-out into New Wave's customer base began in the first half of 2020. The supply agreement provides New Wave with certainty on the pricing and supply of up to 1,000,000 lbs. of the Company's detergent polymers as New Wave volumes increase from both existing and new customers.

In February, we announced our BIO*Asterix™ line of functional additives based on a new range of bio-based chemistries derived from itaconic acid. The Company developed the new BIO*Asterix™ additives over the past three years for a wide range of potential uses, ranging from biodegradable plastics to decorative paints. The Company plans to launch its new product line in stages over the next few years.

I believe the demonstrated value that our polymers provide as key ingredients in everyday consumer products underpin our progress and will generate continued demand growth to create a sizable specialty ingredients company.

Financial Performance

Our financial results for the first half of 2020 show both the increasing uptake of our products and the favourable operating structure we have created to achieve profitability as revenues grow:

First half revenues of $1.1 million were 80% higher than the first half of 2019 and 59% higher than the second half of 2019. First half revenues also represent 84% of revenues for the full year of 2019.

Gross profits were $0.4 million, representing an increase of 129% over the first half of 2019 and 47% over the second half of 2019.

Gross profit margin was 37%, compared to 29% for the first half of 2019 and 35% for the full year of 2019.

Adjusted EBITDA (see note 4 to the financial information) was a loss of $0.6 million, compared to a loss of $1.2 million for the same period in 2019 and a loss of $1.2 million for the second half of 2019, reflecting the continued improvement in the Company's profitability from increasing revenues.

Gross operating profit was a loss of $0.8 million, representing a decrease of 43% from losses of $1.4 million in both the first and second half of 2019.

Financial Resources

We ended the first half of 2020 with the announcement of an equity fundraise to strengthen our balance sheet and support our continued operations.

In March, we announced our efforts to extend the Company's cash runway and conserve available working capital after an equity fundraise was postponed due to uncertainty in the financial markets caused by the Covd-19 pandemic.

In May, we announced that a combination of revenue growth, cost reduction efforts, working capital measures, and government funding programs had extended the Company's cash runway.

In July, we received the required shareholder approvals and completed the equity fundraise. I greatly appreciate the strong support we received from both existing and new shareholders for our progress and development plans.

Covid-19 Pandemic

Major new revenues from a steady stream of new customer products entering the market have allowed us to continue to operate and grow as an essential business throughout the Covid-19 pandemic while addressing several risks.

Most importantly, we are monitoring the safety and health of our employees. We have aligned our operations with government recommendations to limit exposure to Covid-19. We have also eliminated travel while putting new efforts in place to regularly engage with customers and vendors.

Although demand for household cleaning has surged during the Covid-19 pandemic, we believe that the majority of our new revenues come from new customer products that are capturing long-term market share based on new levels of performance, cost and sustainability. I expect our current and new customer projects to continue to advance under the major scenarios for the Covid-19 pandemic.

As detailed above, we successfully managed our operations through a period of funding constraints and now have the working capital to meet the needs of our near-term revenue growth.

We continue to assess risks and potential issues in our supply chain and are taking measures to assure the reliable supply of raw materials from our vendors and delivery of our products to our customers.

Outlook

Itaconix is at a new stage of long-term revenue growth and value creation. The expanding customer base for our current products is generating recurring revenues and financial performance that places us on a discernible path to achieve our near-term goal of sustained revenue growth to reach profitability. We have a pipeline of active customer projects to reach beyond this goal and look firmly to the future with continued optimism.

 

 

 

 

John R. Shaw

Chief Executive Officer

27 October 2020

 

 

Condensed consolidated income statement and statement of comprehensive income

For the six months ended 30 June 2020

 

 

Unaudited

Unaudited

Audited

 

 

6 Months to 30 June

2020

6 Months to 30 June

2019

Year to

31 December

2019

 

 

 

(restated)

 

 

 

 

 

 

 

Notes

$000

$000

$000

Revenue

5

1,086

604

1,288

Cost of sales

 

(683)

(428)

(838)

Gross profit

 

403

176

450

Other operating income

 

71

27

62

Administrative expenses

 

(1,287)

(1,638)

(3,390)

Group operating loss

 

(813)

(1,435)

(2,878)

Finance income

 

-

-

1

Exceptional (expense) / income on movement of contingent consideration

6

-

(816)

1,474

Gain on sale of equity interest in associate

 

-

84

84

Share of profit of associate

 

-

(38)

(38)

Loss before tax

 

(813)

(2,205)

(1,357)

Taxation (expense) credit

 

(1)

(7)

(1)

Loss for the period / year

 

(814)

(2,212)

(1,358)

Other comprehensive income, net of income tax

 

 

 

 

Items that may be reclassified subsequently to profit or loss:

Exchange differences on translated foreign operations

 

110

189

48

Total comprehensive loss for the period / year

 

(704)

(2,023)

(1,310)

 

 

 

 

 

Basic and diluted loss per share

7

(0.3p)

(0.7p)

(0.5p)

 

 

 

 

Condensed consolidated statement of financial position

As at 30 June 2020

 

 

Unaudited

Audited

 

 

As at

As at

 

 

30 June

31 December

 

 

2020

2019

 

 

 

 

 

Notes

$000

$000

Non-current assets

 

 

 

Property, plant and equipment

 

588

701

Right-of-use asset

 

822

920

 

 

1,410

1,621

Current assets

 

 

 

Inventories

 

706

504

Trade and other receivables

 

290

331

Cash and cash equivalents

3

459

765

 

 

1,455

1,600

Total assets

 

2,865

3,221

 

 

 

 

Financed by

 

 

 

Equity shareholders' funds

 

 

 

Equity share capital

 

3,677

3,677

Equity share premium

 

46,135

46,135

Own shares reserve

 

(5)

(5)

Merger reserve

 

31,343

31,343

Share based payment reserve

 

10,324

10,317

Foreign translation reserve

 

(109)

(219)

Retained losses

 

(93,058)

(92,245)

Total deficit

 

(1,693)

(997)

 

 

 

 

Non-current liabilities

 

 

 

Contingent consideration

6

2,274

2,441

Long-term lease liability

 

576

750

 

 

2,850

3,191

Current liabilities

 

 

 

Trade and other payables

 

1,385

707

Short-term lease liability

 

323

320

 

 

1,708

1,027

 

 

 

 

Total liabilities

 

4,558

4,218

 

 

 

 

Total equity and liabilities

 

2,865

3,221

 

 

 

 

      

 

 

 

Interim condensed consolidated statement of cash flows

For the six months ended 30 June 2020

 

 

Unaudited

Unaudited

 

 

6 Months to

30 June

2020

6 Months to

30 June

2019

 

 

 

(restated)

 

 

 

$000

$000

Cash flows from operating activities

 

 

 

Operating loss

 

(813)

(2,205)

Adjustments for:

 

 

 

Finance expense

 

-

2

Depreciation of property, plant and equipment

 

108

109

Depreciation of right-of-use asset

 

99

106

Gain on disposal of equipment

 

(15)

(13)

Gain on sale of investment in associate

 

-

(84)

Share of loss from associate

 

-

38

Recovery of loan to associate

 

-

(29)

Share option charge

 

8

15

Revaluation of deferred consideration

 

-

816

(Gain) / loss on foreign exchange

 

(57)

189

Taxation

 

(1)

(7)

Increase in inventories

 

(202)

(161)

Decrease in receivables

 

40

300

Increase in payables

 

496

70

Net cash (outflow) from operating activities

 

(337)

(854)

 

 

 

 

Cash flows from investing activities

 

 

 

Investment in associate undertaking, net of transaction costs

 

-

211

Repayment of the loan to associate

 

-

57

Interest paid on loan to associates

 

-

6

Proceeds from sale of property, plant and equipment

 

20

40

Purchase of property, plant and equipment

 

-

(32)

Net cash inflow from investing activities

 

20

282

 

 

 

 

Cash flows from financing activities

 

 

 

Proceeds from government secured debt

 

183

-

Lease payments

 

(183)

(108)

Interest expense on lease payments

 

11

9

Net cash (outflow) from financing activities

 

11

(99)

 

 

 

 

Net (outflow) in cash and cash equivalents

 

(306)

(671)

Cash and cash equivalents at beginning of the period

 

765

2,655

Cash and cash equivalents at end of the period

 

459

1,984

Notes to the interim condensed consolidated financial statements

1. General information

These unaudited interim condensed financial statements of Itaconix plc for the six months ended 30 June 2020 were approved for issue in accordance with a resolution of the Board on 27 October 2020. Itaconix plc is a public limited company incorporated in the United Kingdom whose shares are traded on the AIM Market of the London Stock Exchange.

This half-yearly financial report is also available on the Group's website at https://itaconix.com/investor/reports-documents/.

2. Accounting policies

These interim consolidated financial statements have been prepared using accounting policies based on International Financial Reporting Standards (IFRS and IFRIC Interpretations) issued by the International Accounting Standards Board ("IASB") as adopted for use in the EU. They do not include all disclosures that would otherwise be required in a complete set of financial statements and should be read in conjunction with the 31 December 2019 ('2019') Annual Report. The financial information for the half years ended 30 June 2020 and 30 June 2019 does not constitute statutory accounts within the meaning of Section 434 (3) of the Companies Act 2006 and both periods are unaudited.

The annual financial statements of Itaconix Plc ('the Group') are prepared in accordance with IFRS as adopted by the European Union. The comparative financial information for the year ended 31 December 2019 included within this report does not constitute the full statutory Annual Report for that period. The statutory Annual Report and Financial Statements for 2019 have been filed with the Registrar of Companies. The Independent Auditors' Report on the Annual Report and Financial Statements for the year ended 31 December 2019 was unqualified, did draw attention to a matter by way of emphasis, being going concern, and did not contain a statement under 498(2) - (3) of the Companies Act 2006.

The interim condensed consolidated financial statements are presented in US dollars and all values are rounded to the nearest thousand ($'000) except when otherwise indicated. The interim condensed consolidated financial statements are prepared on the historical cost basis except for contingent consideration which have been measured at fair value.

The Group has applied the same accounting policies and methods of computation in its interim consolidated financial statements as in its 31 December 2019 annual financial statements, except for those that relate to new standards and interpretations effective for the first time for periods beginning on (or after) 1 January 2020 and will be adopted in the 2020 financial statements. There are deemed to be no new and amended standards and/or interpretations that will apply for the first time in the next annual financial statements that are expected to have a material impact on the Group.

Reporting Currency

As noted in the Group's 2019 Annual Report, the Board decided to change the reporting currency for the year end 31 December 2019 to US Dollars (USD). The Board therefore believes that USD financial reporting provides a reliable and more relevant presentation of the Group's financial position, funding and treasury functions, financial performance, and its cash flows. Coupled with the evolution of the business, the Group's shareholder base is now largely comprised of foreign investors to whom financial reporting in GBP is of limited relevance. Internally, the Board also bases its performance evaluation and many investment decisions on USD financial information. As a result of this updated accounting policy, the comparative information for the period ended 30 June 2019, has been restated in USD.

Going concern

This Interim Report has been prepared on the assumption that the business is a going concern. In reaching their assessment, the Directors have considered a period extending at least 12 months from the date of approval of this half-yearly financial report. This assessment has included consideration of the forecast performance of the business for the foreseeable future and the cash available to the Group. As such, the Directors have concluded that there exists a material uncertainty which may cast doubt as to the Group's ability to continue as a going concern. However, taking account of the Group's working capital at the date of this report, the Group's current revenue growth, and current shareholder approval to raise capital if needed, the Directors believe the Group will continue as a going concern for the foreseeable future. The interim financial statements do not include the adjustments that would be required if the Group were unable to continue as a going concern.

Risks and uncertainties

The principal risks and uncertainties facing the Group remain broadly consistent with the Principal Risks and Uncertainties reported in Itaconix plc's 31 December 2019 Annual Report. Since the 2019 Annual Report, the Board have been monitoring and mitigating the effects of the following international events on the Group's business:

Covid-19

In March 2020, the World Health Organisation declared a global pandemic due to the spread of Covid-19. The pandemic has restricted people's movements globally and caused economic disruption and uncertainty to supply chain and customer stability. The impact of Covid-19 has been considered as part of the Group's going concern assessment with a focus on the impact on the Group's revenues, working capital and non-current assets. Management have considered the impact a non-adjusting balance sheet event.

Throughout the Covid-19 pandemic, the Group has maintained operations as an essential business. Extraordinary efforts to conserve available cash were taken in March 2020 to manage the Group's working capital. In addition, new funding, via an equity raise (see Note 8), was sourced in July 2020. While some customer formulation activities have slowed, the surge in demand for household detergents has significantly increased order volumes for the Group's detergent polymers. Effective customer engagement has continued without travel through adaptation and innovation in customer communication and engagement.

Brexit

The United Kingdom ('UK') formally left the European Union ('EU') on 30 January 2020. The UK is now in a transition period, being an intermediary arrangement covering matters like trade and border arrangements, citizens' rights and jurisdiction on matters including dispute resolution. The transition period is currently due to end on 31 December 2020 and negotiations are ongoing to determine and conclude a formal agreement. The Directors are closely monitoring the situation and currently deem that the effects of Brexit will not have a significant impact on the Group's operations given that the Group operates predominantly outside the UK.

3. Cash and cash equivalents

 

Unaudited

Audited

 

As at

As at

 

30 June

31 December

 

2020

 

2019

 

 

 

 

$000

$000

Cash at bank and in hand

459

765

 

459

765

 

 

 

4. Reconciliation of Operating Loss to Adjusted EBITDA

The detail below shows the reconciliation of operating loss to earnings before exceptional expense/(income), gain on sale of equity interest in associate, share of profit of associate, interest, taxes, depreciation and amortization (Adjusted EBITDA).

 

 

 

Unaudited

 

Unaudited

Audited

 

 

 

6 Months to 30 June

2020

6 Months to 30 June

2019

Year to 31 December

2019

 

 

 

(restated)

 

 

 

 

 

 

 

 

$000

$000

$000

Loss for the period

 

(814)

(2,212)

(1,358)

Exceptional expense (income) on movement of contingent consideration

 

-

816

(1,474)

Gain on sale of equity interest in associate

 

-

(84)

(84)

Share of profit of associate

 

-

38

38

Interest

 

-

(1)

(1)

Taxes

 

1

7

1

Depreciation

 

207

215

421

Adjusted EBITDA

 

(606)

(1,221)

(2,457)

          

5. Segmental analysis

Revenue by business segment:

The Group has one segment, the Specialty Ingredients segment, which designs and manufactures proprietary specialty polymers to meet customers' needs in the personal and consumer health care, homecare and industrial sectors. This segment makes up the continuing operations above.

Net assets of the Group are attributable solely to the UK and US.

 

 

 

Unaudited

6 months to

30 June 2020

Unaudited

6 months to

30 June 2019

Audited

Year to 31 December 2019

 

$000

$000

$000

 

 

(restated)

 

Revenue

 

 

 

Sale of goods

1,086

604

1,288

Segment revenue

1,086

604

1,288

Results

 

 

 

Depreciation & amortisation

207

215

421

Segment loss

(822)

(1,435)

(2,878)

Operating assets

2,865

5,089

3,221

Operating liabilities

4,558

6,930

4,218

Other disclosure:

 

 

 

Capital expenditure*

Nil

32

39

*Capital expenditure consists of additions of property, plant and equipment, and intangible assets including assets from the acquisition of subsidiaries.

Geographical information

 

 

Revenues

Net assets

 

Unaudited

Unaudited

Audited

Unaudited

Audited

 

 

Six Months to

30 June 2020

Six Months to

30 June 2019

Year to 31 December 2019

Six Months to

30 June 2020

Year to 31 December 2019

 

 

 

(restated)

 

 

 

 

 

 

 

 

 

 

 

 

$000

$000

$000

$000

$000

 

Europe

93

125

160

(1,836)

(2,195)

 

North America

993

479

1,128

499

1,198

 

 

1,086

604

1,288

(1,337)

(997)

 

        

The revenue information above is based on the location of the customer.

6. Contingent consideration

 

$'000

As at 31 December 2019 (Audited)

2,441

Movement in fair value and discounting unwind

-

Movement in foreign exchange

(167)

As at 30 June 2020 (Unaudited)

2,274

During 2018, in conjunction with the fund raise, a restructuring of the contingent consideration was executed. The contingent consideration was restructured into two components:

· A one-time issue of 15 million new Itaconix plc shares to the Sellers.

· The continuation of the previous contingent consideration mechanism (i.e. up to $6m in shares), but with the window of time for potential achievement expanded to the end of 2023 (from the end of 2020) and including all the revenues of the Group (which are primarily from products based on the acquired technology in any event).

It should also be noted that the second component summarised above is intended to serve as an incentive programme for the two members of management (John Shaw and Yvon Durant) who are also Sellers and are entitled to 63% of the total contingent consideration. Accordingly, they are not eligible for any cash bonus or other share incentive programme until the end of 2020. Simultaneously, the merger agreement with the former shareholders of Itaconix Corporation and related agreements were amended to remove various restrictive clauses, including minimum funding requirements and employment terms.

Based on the share price at the execution of the restructuring agreement in 2018, the 15m shares had a value of £0.3m which was expensed immediately.

In respect of 2020, the deferred consideration was valued using a discounted cash flow-based assessment of the expected sales of the relevant products extracted from the latest Board approved forecasts, consistent with the approach in prior years. A discount rate of 11.2% was used. The valuation includes elements which are unobservable and which have a significant impact on the fair value. Accordingly, contingent consideration is classified as Level 3 fair value measurement.

The value of the adjusted contingent component using the latest Board approved forecasts and assumptions as above is $2.3m (31 December 2019 - $2.4m)

 

 

As a result of the changed revenue forecasts, earn out period, and discount rate from the original value assessments, the contingent consideration at 31 December 2019 was reduced to $2.4m. Sensitivity analysis was also performed, summarised as follows:

· If the sales in the period 2020 to 2022 were reduced by $1.0m, the fair value would be reduced by approximately $0.4m

· A 1% increase in the discount rate would reduce the fair value by $55k

Since the forecasts used were a conservative base case, the computed fair value was deemed appropriate.

7. Weighted-average number of ordinary shares

 

Unaudited

Unaudited

 

6 Months to

30 June 2020

6 Months to

30 June 2019

 

 

 

Weighted average number of ordinary shares for the

 purposes of basic and diluted loss per share ('000)

269,130

269,130

 

8. Events after the reporting period

In July 2020, the Group successfully raised gross proceeds of $2.2 million (£1.8 million) via an oversubscribed placing and subscription from existing and new investors at the Issue Price of 1.1 pence ($0.01375) per share. A total of 163,318,182 new Ordinary Shares were placed. The net proceeds of the Placing and Subscription are expected to provide sufficient funding for the Company until at least the end of 2021 during which the Company expects to make significant progress towards its strategic objective.

Subsequent to the reporting period, the Group surrendered its leased building in Deeside, United Kingdom on 3 September 2020. The Group is now released from future rent and building related expenses.

9. Cautionary statement

This document contains certain forward-looking statements relating to Itaconix plc ('the Company'). The Company considers any statements that are not historical facts as "forward-looking statements". They relate to events and trends that are subject to risk and uncertainty that may cause actual results and the financial performance of the Company to differ materially from those contained in any forward-looking statement. These statements are made by the Directors in good faith based on information available to them and such statements should be treated with caution due to the inherent uncertainties, including both economic and business risk factors, underlying any such forward-looking information. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR MRBBTMTJTTBM
Date   Source Headline
19th Apr 20247:00 amRNSGrants of Options & PDMR dealings
15th Apr 20247:00 amRNSPreliminary Results and Notice of AGM
8th Apr 20247:00 amRNSNotice of Results
2nd Apr 20247:00 amRNSTrading Statement
27th Feb 20247:00 amRNSTrading Update
9th Feb 20247:00 amRNSAppointment of Non-Executive Director
26th Jan 20247:00 amRNSAppointment: Nominated Adviser and Sole Broker
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
30th Oct 20237:00 amRNSDirector/PDMR Shareholding
26th Oct 20235:28 pmRNSDirector/PDMR Shareholding
19th Oct 20235:08 pmRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
5th Oct 202311:01 amRNSHoldings in Company
12th Sep 20237:00 amRNSHalf year results
5th Sep 20237:00 amRNSNotice of Interim Results and Presentations
22nd Aug 20237:00 amRNSShare Consolidation & Total Voting Rights
15th Aug 20237:00 amRNSShare Consolidation
12th Jul 20237:00 amRNSTrading Update
28th Jun 202312:29 pmRNSAGM Statement
5th Jun 20237:00 amRNSFinal Results
24th May 20237:00 amRNSNotice of Final Results, Briefings, and AGM
25th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
2nd Mar 20233:25 pmRNSTR-1
1st Mar 20237:00 amRNSAward from Frost & Sullivan
28th Feb 20236:03 pmRNSTR-1
28th Feb 20235:04 pmRNSTR-1
28th Feb 20233:09 pmRNSTR-1
23rd Feb 20237:00 amRNSTR-1
22nd Feb 202312:28 pmRNSResults of Open Offer, GM and Total Voting Rights
15th Feb 20237:00 amRNSInvestor Presentation following GM on 22 Feb 2023
3rd Feb 20237:00 amRNSPlacing, Subscription and Open Offer; Notice of GM
5th Jan 20237:00 amRNSBoard Change
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSItaconix and Brenntag Promote Sustainable Cleaning
14th Sep 20227:00 amRNSHalf year results
13th Sep 202211:05 amRNSSecond Price Monitoring Extn
13th Sep 202211:00 amRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSNotice of Results
5th Sep 20227:00 amRNSItaconix and Croda Renew Supply Agreement
20th Jul 20227:00 amRNSBoard Change
13th Jul 20227:00 amRNSTrading Update
5th Jul 20227:00 amRNSDirectorate Change
1st Jul 20222:37 pmRNSResult of AGM
1st Jul 20229:00 amRNSPrice Monitoring Extension
1st Jul 20227:00 amRNSAGM Statement and Notice of Capital Markets Event
29th Jun 20227:00 amRNSNotice of Capital Markets Webinar
8th Jun 20229:04 amRNSFinal Results - replacement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.